Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits

Parkinsonism and Related Disorders

Volumn 7, Issue 2, 2001, Pages 97-105

  Fredriksson, A ^a   Schroder N ^b   Eriksson, P ^a   Izquierdo, I ^b   Archer, T ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Basal ganglia; C57 Bl 6 mice; Dopamine; Frontal cortex; Habituation; Iron overload; Metabolites; MPTP; Neonatal; Spontaneous motor behaviour; Total iron

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FERROUS SUCCINATE; GLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN DEVELOPMENT; CONTROLLED STUDY; DOPAMINE METABOLISM; FRONTAL CORTEX; HABITUATION; IRON OVERLOAD; LOCOMOTION; MOTOR ACTIVITY; MOUSE; NEWBORN; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 0035119808     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00028-6     Document Type: Article

References (65)

1. The development and modifiability of the cerebral cortex. Overview
2. A histochemical study of iron-positive cells in the developing rat brain
3. Iron in brain function and dysfunction with emphasis on Parkinson's disease
4. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers
5. Magnetic resonance imaging in parkinsonism
6. Free radicals in brain metabolism and pathology
7. Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, aminoaciduria [see comments]
8. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
9. The role of transition metals in the pathogenesis of Parkinson's disease
10. Hallervorden-Spatz syndrome and brain iron metabolism
11. Increased nigral iron content in postmortem parkinsonian brain [letter]
12. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron
13. Transition metals, ferritin, glutathione, ascorbic acid in parkinsonian brains
14. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders
15. Developmental changes in transferrin and iron uptake by the brain in the rat
16. Transferrin and iron uptake by the brain: effects of altered iron status
17. An autoradiographic study of the uptake and distribution of iron by the brain of the young rat
18. The ontogeny of behaviour in the albino rat
19. Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat
20. Exposure to an organophosphate (DFP) during a defined period in neonatal life induces permanent changes in brain muscarinic receptors and behaviour in adult mice
21. Exposure to DDT during a defined period in neonatal life induces permanent changes in brain muscarinic receptors and behaviour in adult mice
22. Developmental neurotoxicity of environmental agents in the neonate
23. MPTP neurotoxicity: an overview and characterization of phases of toxicity
24. MPTP-induced hypoactivity in mice: reversal by L-dopa
25. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease
26. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
27. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
28. Dissociation between biochemical and behavioral recovery in MPTP- treated mice
29. MPTP-induced behavioural and biochemical deficits: a parametric analysis
30. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice
31. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
32. Effect of the competitive NMDA antagonist, CGP 40116, a low dose of L-Dopa on the motor activity deficit of MPTP-treated mice
33. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice
34. Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period
35. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man
36. Behavioural pharmacology of glutamate receptors in the basal ganglia
37. Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat
38. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects
39. Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists
40. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain
41. Behavioural effects of prenatal metallic mercury inhalation exposure in rats
42. Behavioural effects of neonatal metallic mercury exposure in rats
43. Prenatal coexposure to metallic mercury vapour and methylmercury produce interactive behavioural changes in adult rats
44. Cognitive changes in mice following moderate MPTP exposure
45. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys
46. Neurobehavioral dysfunctions associated with dietary iron overload
47. Multiple transmitters modulate prepulse inhibition of startle: relevance to schizophrenia
48. Progressive changes in striatal dopaminergic markers, nigral volume, rotational behavior following iron infusion into the rat substantia nigra
49. Behavioral, physiological, neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons
50. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study
51. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis
52. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease
53. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
54. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease [In Process Citation]
55. Iron overload and mitochondrial diseases [letter; comment]
56. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures
57. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, biochemical study
58. Nuclear microscope analysis in Alzheimer's and Parkinson's disease: a review
59. The pivotal role of iron in NF-(kappa)B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators
60. 125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys